網膜静脈閉塞症に伴う黄斑浮腫に対するラニビズマブの硝子体内注射と硝子体手術の効果

Outcome of intravitreal ranibizumab with or without vitrectomy in retinal vein occlusion with macular edema

要約　目的：黄斑浮腫がある網膜静脈閉塞症に対してラニビズマブの硝子体内投与を行い，硝子体手術を実施またはしなかった症例での成績の報告。対象と方法：過去41月間にラニビズマブの硝子体内投与を行った黄斑浮腫を伴う網膜静脈閉塞症30眼を対象とした。網膜分枝静脈閉塞症17眼，網膜中心静脈閉塞症13眼である。硝子体手術は，それぞれ17眼中10眼と13眼中6眼に行った。視力はlogMARで評価し，平均10か月以上の経過を追った。結果：網膜静脈分枝閉塞症では，注射群，手術群ともに，有意に視力が改善し，中心窩厚の平均値も，両群ともに減少した。網膜中心静脈閉塞症群では，視力の平均値に有意な変化はなかった。結論：黄斑浮腫がある網膜静脈分枝閉塞症に対するラニビズマブの硝子体内投与と硝子体手術では，ともに中心窩厚が減少し，視力が改善した。

Abstract.　Purpose：To report the outcome of intravitreal ranibizumab or vitrectomy in retinal vein occlusion with macular edema. Cases and Method：This retrospective study was made on 30 eyes of retinal vein occlusion treated during the past 41 months. The series comprised 17 eyes with branch retinal vein occlusion（BRVO）and 13 eyes with central retinal vein occlusion（CRVO）. All the eyes received intraviteal ranibizumab in one or more sessions. Vitrectomy was performed in 10 out of 17 eyes with BRVO and in 6 out of 13 eyes with CRVO. Cases were followed up for an average of 10 months. Results：Visual acuity improved in average in eyes with BRVO irrespective of additional vitrectomy. Foveal thickness decreased in average in eyes with BRVO. There was no significant change in visual acuity in eyes with CRVO. Conclusion：Visual acuity improved following intravitreal ranibizumab with or without vitrectomy in eyes of BRVO with macular edema.